Search

Your search keyword '"van der Velden, Vincent"' showing total 928 results

Search Constraints

Start Over You searched for: Author "van der Velden, Vincent" Remove constraint Author: "van der Velden, Vincent"
928 results on '"van der Velden, Vincent"'

Search Results

3. The gray area of RQ-PCR-based measurable residual disease: subdividing the “positive, below quantitative range” category

4. Analysis of measurable residual disease by IG/TR gene rearrangements: quality assurance and updated EuroMRD guidelines

5. Baseline immunophenotypic profile of bone marrow leukemia cells in acute myeloid leukemia with nucleophosmin-1 gene mutation: a EuroFlow study

6. Treatment of primary plasma cell leukaemia with carfilzomib and lenalidomide-based therapy (EMN12/HOVON-129): final analysis of a non-randomised, multicentre, phase 2 study

7. IKZF1 gene deletions drive resistance to cytarabine in B-cell precursor acute lymphoblastic leukemia

8. Inotuzumab ozogamicin as single agent in pediatric patients with relapsed and refractory acute lymphoblastic leukemia: results from a phase II trial

9. The tumor suppressor MIR139 is silenced by POLR2M to promote AML oncogenesis

10. Longitudinal minimal residual disease assessment in multiple myeloma patients in complete remission – results from the NMSG flow-MRD substudy within the EMN02/HO95 MM trial

11. Clofarabine added to intensive treatment in adult patients with newly diagnosed ALL: the HOVON-100 trial

12. Expert-independent classification of mature B-cell neoplasms using standardized flow cytometry: a multicentric study

14. Benefits and risks of clofarabine in adult acute lymphoblastic leukemia investigated in depth by multi‐state modeling

15. Association of Altered Plasma Lipidome with Disease Severity in COVID-19 Patients

16. Minimal residual disease, long-term outcome, and IKZF1 deletions in children and adolescents with Down syndrome and acute lymphocytic leukaemia: a matched cohort study

18. A phase 1 study of inotuzumab ozogamicin in pediatric relapsed/refractory acute lymphoblastic leukemia (ITCC-059 study)

22. Automated identification of leukocyte subsets improves standardization of database-guided expert-supervised diagnostic orientation in acute leukemia: a EuroFlow study

23. Association of Altered Plasma Lipidome with Disease Severity in COVID-19 Patients

24. Benefits and risks of clofarabine in adult acute lymphoblastic leukemia investigated in depth by multi-state modeling

25. The gray area of RQ-PCR-based measurable residual disease:subdividing the “positive, below quantitative range” category

26. The Evolving Landscape of Flowcytometric Minimal Residual Disease Monitoring in B-Cell Precursor Acute Lymphoblastic Leukemia

27. Phenotypic profiling of CD34+ cells by advanced flow cytometry improves diagnosis of Juvenile Myelomonocytic Leukemia

28. Bosutinib in Resistant and Intolerant Pediatric Patients With Chronic Phase Chronic Myeloid Leukemia: Results From the Phase I Part of Study ITCC054/COG AAML1921

29. Association of Altered Plasma Lipidome with Disease Severity in COVID-19 Patients

30. Benefits and risks of clofarabine in adult acute lymphoblastic leukemia investigated in depth by multi-state modeling

31. Bosutinib in Resistant and Intolerant Pediatric Patients With Chronic Phase Chronic Myeloid Leukemia:Results From the Phase I Part of Study ITCC054/COG AAML1921

32. Phenotypic profiling of CD34+ cells by advanced flow cytometry improves diagnosis of juvenile myelomonocytic leukemia

33. Normal and malignant cells are homogeneously distributed in the bone marrow of children.

34. Autologous haematopoietic stem-cell transplantation versus bortezomib–melphalan–prednisone, with or without bortezomib–lenalidomide–dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study

35. Inotuzumab ozogamicin combined with chemotherapy in pediatric B-cell precursor CD22+ acute lymphoblastic leukemia: results of the phase IB ITCC-059 trial

37. More precisely defining risk peri-HCT in pediatric ALL: pre- vs post-MRD measures, serial positivity, and risk modeling

40. Minimal residual disease assessment by multiparameter flow cytometry in transplant-eligible myeloma in the EMN02/HOVON 95 MM trial

41. Bosutinib in Resistant and Intolerant Pediatric Patients With Chronic Phase Chronic Myeloid Leukemia: Results From the Phase I Part of Study ITCC054/COG AAML1921.

42. Analytical assay validation for acute myeloid leukemia measurable residual disease assessment by multiparametric flow cytometry

43. ABL-class Genomic Breakpoint Q-PCR: A Patient-specific Approach for MRD Monitoring in Acute Lymphoblastic Leukemia

44. Basophil-lineage commitment in acute promyelocytic leukemia predicts for severe bleeding after starting therapy

45. CD34+CD38− leukemic stem cell frequency to predict outcome in acute myeloid leukemia

46. Phenotypic profiling of CD34+ cells by advanced flow cytometry improves diagnosis of juvenile myelomonocytic leukemia

48. P318: LOSS OF SCARNA12 RESULTS IN ABERRANT SPLICING OF TARGET GENES AND DOWNREGULATION OF P53 IN B-CELL PRECURSOR ACUTE LYMPHOBLASTIC LEUKEMIA (BCP-ALL)

49. P872: EFFICACY OF DARATUMUMAB PLUS BORTEZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE IN PATIENTS WITH MULTIPLE MYELOMA PRESENTING WITH EXTRAMEDULLARY DISEASE: A EUROPEAN MYELOMA NETWORK STUDY (EMN19)

50. P475: EMERGING LEUKEMIA ASSOCIATED IMMUNOPHENOTYPES (LAIPS) IN BONE MARROW OF ACUTE MYELOID LEUKEMIA PATIENTS AFTER INTENSIVE CHEMOTHERAPY.

Catalog

Books, media, physical & digital resources